Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell Lines

Therapeutic efficacy of cisplatin-based chemotherapy for advanced-stage urothelial carcinoma (UC) is limited by drug resistance. The nuclear factor (erythroid-derived 2)-like 2 (NRF2) pathway is a major regulator of cytoprotective responses. We investigated its involvement in cisplatin resistance in...

Descripción completa

Detalles Bibliográficos
Autores principales: Skowron, Margaretha A., Niegisch, Günter, Albrecht, Philipp, van Koeveringe, Gommert, Romano, Andrea, Albers, Peter, Schulz, Wolfgang A., Hoffmann, Michèle J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578070/
https://www.ncbi.nlm.nih.gov/pubmed/28767070
http://dx.doi.org/10.3390/ijms18081680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578070/
https://www.ncbi.nlm.nih.gov/pubmed/28767070
http://dx.doi.org/10.3390/ijms18081680

Ejemplares similares